A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
68
Participants
Timeline
Start Date
January 1, 2026
Primary Completion Date
November 30, 2029
Study Completion Date
November 30, 2029
Conditions
Head and Neck Cancer
Interventions
DRUG
cemiplimab+fianlimab
Fianlimab 1600 mg + Cemiplimab 350 mg FDC
DRUG
Cemiplimab
350 mg
All Listed Sponsors
lead
University of Chicago
OTHER
NCT07179315 - A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment | Biotech Hunter | Biotech Hunter